Thus, the low expression of ErbB2 and ErbB3 stabilized the PI3K/Akt signaling pathway in hematologic tumors (Table 1), thereby enabling compound 23 to exhibit more potent antitumor efficacy than against solid tumor cells. The gene discussed is AKT1; the disease is hematopoietic and lymphoid cell neoplasm.